Mignon L Loh1,2, Sarah K Tasian3,4,5, Karen R Rabin6, Patrick Brown7,8, Daniel Magoon7,8, Joel M Reid9, Xuejun Chen10, Charlotte H Ahern11, Brenda J Weigel12, Susan M Blaney6. 1. Department of Pediatrics, UCSF Benioff Children's Hospital, San Francisco, California. 2. Helen Diller Family Comprehensive Cancer Center, San Francisco, California. 3. Division of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania. 4. Department of Pediatrics and Abramson Cancer Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania. 5. Department of Pediatrics, Division of Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania. 6. Division of Pediatric Hematology/Oncology, Texas Children's Cancer Center, Baylor College of Medicine, Houston, Texas. 7. Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, Maryland. 8. Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland. 9. College of Medicine, Mayo Clinic, Rochester, Minnesota. 10. Incyte Corporation, Wilmington, Delaware. 11. Children's Oncology Group, Arcadia, California. 12. University of Minnesota, Minneapolis, Minnesota.
Abstract
BACKGROUND: Ruxolitinib, an orally bioavailable JAK1/JAK2 inhibitor, may treat cancers with CRLF2 and/or JAK pathway mutations. PROCEDURE: A phase 1 trial of ruxolitinib was performed to determine the maximum tolerated or recommended phase 2 dose, dose-limiting toxicities (DLTs), pharmacokinetics (PK), and pharmacodynamics (PD) in children with recurrent/refractory solid tumors (STs). Ruxolitinib was administered twice daily (BID) in 28-day cycles at five dose levels (15, 21, 29, 39, and 50 mg/m(2)/dose). PK and PD studies were performed during cycle 1. Toxicity, preliminary efficacy, and PK/PD were also assessed in children with relapsed/refractory hematologic malignancies (HMs). RESULTS: Forty-nine patients were enrolled, 28 with STs (dose escalation cohort) and 21 with HMs. Ruxolitinib was well-tolerated with one DLT per cohort of six patients at dose levels (DLs) 2-5. One patient with an ST had grade 5 multi-organ failure at DL2. One patient each at DL3 and DL4 had a grade 4 neutropenia, and one patient at DL5 had a grade 4 creatinine phosphokinase elevation. No objective responses were observed in patients with STs. One patient with polycythemia vera achieved a partial response and received 18 cycles of ruxolitinib. The PK of ruxolitinib were similar to that in adults. Partial inhibition of phosphorylated JAK2, STAT5, and S6 was observed in in vitro plasma inhibitory activity PD assay. CONCLUSION: Ruxolitinib was well tolerated in children with refractory cancer. The recommended phase 2 dose for continuous BID oral administration is 50 mg/m(2)/dose. Subsequent evaluation of ruxolitinib in combination with cytotoxic chemotherapy in children, adolescents, and young adults with JAK-mutant leukemias is planned.
BACKGROUND:Ruxolitinib, an orally bioavailable JAK1/JAK2 inhibitor, may treat cancers with CRLF2 and/or JAK pathway mutations. PROCEDURE: A phase 1 trial of ruxolitinib was performed to determine the maximum tolerated or recommended phase 2 dose, dose-limiting toxicities (DLTs), pharmacokinetics (PK), and pharmacodynamics (PD) in children with recurrent/refractory solid tumors (STs). Ruxolitinib was administered twice daily (BID) in 28-day cycles at five dose levels (15, 21, 29, 39, and 50 mg/m(2)/dose). PK and PD studies were performed during cycle 1. Toxicity, preliminary efficacy, and PK/PD were also assessed in children with relapsed/refractory hematologic malignancies (HMs). RESULTS: Forty-nine patients were enrolled, 28 with STs (dose escalation cohort) and 21 with HMs. Ruxolitinib was well-tolerated with one DLT per cohort of six patients at dose levels (DLs) 2-5. One patient with an ST had grade 5 multi-organ failure at DL2. One patient each at DL3 and DL4 had a grade 4 neutropenia, and one patient at DL5 had a grade 4 creatinine phosphokinase elevation. No objective responses were observed in patients with STs. One patient with polycythemia vera achieved a partial response and received 18 cycles of ruxolitinib. The PK of ruxolitinib were similar to that in adults. Partial inhibition of phosphorylated JAK2, STAT5, and S6 was observed in in vitro plasma inhibitory activity PD assay. CONCLUSION:Ruxolitinib was well tolerated in children with refractory cancer. The recommended phase 2 dose for continuous BID oral administration is 50 mg/m(2)/dose. Subsequent evaluation of ruxolitinib in combination with cytotoxic chemotherapy in children, adolescents, and young adults with JAK-mutant leukemias is planned.
Authors: K R Schultz; A Carroll; N A Heerema; W P Bowman; A Aledo; W B Slayton; H Sather; M Devidas; H W Zheng; S M Davies; P S Gaynon; M Trigg; R Rutledge; D Jorstad; N Winick; M J Borowitz; S P Hunger; W L Carroll; B Camitta Journal: Leukemia Date: 2014-01-20 Impact factor: 11.528
Authors: Kathryn G Roberts; Yongjin Li; Debbie Payne-Turner; Richard C Harvey; Yung-Li Yang; Deqing Pei; Kelly McCastlain; Li Ding; Charles Lu; Guangchun Song; Jing Ma; Jared Becksfort; Michael Rusch; Shann-Ching Chen; John Easton; Jinjun Cheng; Kristy Boggs; Natalia Santiago-Morales; Ilaria Iacobucci; Robert S Fulton; Ji Wen; Marcus Valentine; Cheng Cheng; Steven W Paugh; Meenakshi Devidas; I-Ming Chen; Shalini Reshmi; Amy Smith; Erin Hedlund; Pankaj Gupta; Panduka Nagahawatte; Gang Wu; Xiang Chen; Donald Yergeau; Bhavin Vadodaria; Heather Mulder; Naomi J Winick; Eric C Larsen; William L Carroll; Nyla A Heerema; Andrew J Carroll; Guy Grayson; Sarah K Tasian; Andrew S Moore; Frank Keller; Melissa Frei-Jones; James A Whitlock; Elizabeth A Raetz; Deborah L White; Timothy P Hughes; Jaime M Guidry Auvil; Malcolm A Smith; Guido Marcucci; Clara D Bloomfield; Krzysztof Mrózek; Jessica Kohlschmidt; Wendy Stock; Steven M Kornblau; Marina Konopleva; Elisabeth Paietta; Ching-Hon Pui; Sima Jeha; Mary V Relling; William E Evans; Daniela S Gerhard; Julie M Gastier-Foster; Elaine Mardis; Richard K Wilson; Mignon L Loh; James R Downing; Stephen P Hunger; Cheryl L Willman; Jinghui Zhang; Charles G Mullighan Journal: N Engl J Med Date: 2014-09-11 Impact factor: 91.245
Authors: Shannon L Maude; Sarah K Tasian; Tiffaney Vincent; Junior W Hall; Cecilia Sheen; Kathryn G Roberts; Alix E Seif; David M Barrett; I-Ming Chen; J Racquel Collins; Charles G Mullighan; Stephen P Hunger; Richard C Harvey; Cheryl L Willman; Jordan S Fridman; Mignon L Loh; Stephan A Grupp; David T Teachey Journal: Blood Date: 2012-09-06 Impact factor: 22.113
Authors: Yang Y Ding; Julie W Stern; Tracey F Jubelirer; Gerald B Wertheim; Fumin Lin; Fengqi Chang; Zhaohui Gu; Charles G Mullighan; Yong Li; Richard C Harvey; I-Ming Chen; Cheryl L Willman; Stephen P Hunger; Marilyn M Li; Sarah K Tasian Journal: Haematologica Date: 2018-05-17 Impact factor: 9.941
Authors: Kimberly M Arnold; Lynn M Opdenaker; Nicole J Flynn; Daniel Kwesi Appeah; Jennifer Sims-Mourtada Journal: Int J Radiat Biol Date: 2020-01-06 Impact factor: 2.694
Authors: A M Savino; J Sarno; L Trentin; M Vieri; G Fazio; M Bardini; C Bugarin; G Fossati; K L Davis; G Gaipa; S Izraeli; L H Meyer; G P Nolan; A Biondi; G Te Kronnie; C Palmi; G Cazzaniga Journal: Leukemia Date: 2017-03-23 Impact factor: 11.528
Authors: Sarah K Tasian; David T Teachey; Yong Li; Feng Shen; Richard C Harvey; I-Ming Chen; Theresa Ryan; Tiffaney L Vincent; Cheryl L Willman; Alexander E Perl; Stephen P Hunger; Mignon L Loh; Martin Carroll; Stephan A Grupp Journal: Blood Date: 2016-10-24 Impact factor: 22.113
Authors: Susan R Rheingold; Sarah K Tasian; James A Whitlock; David T Teachey; Michael J Borowitz; Xiaowei Liu; Charles G Minard; Elizabeth Fox; Brenda J Weigel; Susan M Blaney Journal: Br J Haematol Date: 2017-03-14 Impact factor: 6.998